JP6716785B2 - Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 - Google Patents

Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 Download PDF

Info

Publication number
JP6716785B2
JP6716785B2 JP2019508953A JP2019508953A JP6716785B2 JP 6716785 B2 JP6716785 B2 JP 6716785B2 JP 2019508953 A JP2019508953 A JP 2019508953A JP 2019508953 A JP2019508953 A JP 2019508953A JP 6716785 B2 JP6716785 B2 JP 6716785B2
Authority
JP
Japan
Prior art keywords
compound
tenofovir
hiv
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528280A5 (enExample
JP2019528280A (ja
Inventor
マイケル グラウプ，
マイケル グラウプ，
スティーブン ジェイ． ヘンリー，
スティーブン ジェイ． ヘンリー，
ジョン オー． リンク，
ジョン オー． リンク，
チャールズ ウィリアム ロー，
チャールズ ウィリアム ロー，
ローランド ディー． サイトウ，
ローランド ディー． サイトウ，
スコット ディー． シュローダー，
スコット ディー． シュローダー，
ディミトリオス ステファニディス，
ディミトリオス ステファニディス，
ウィンストン シー． ツェ，
ウィンストン シー． ツェ，
ジェニファー アール． ジャン，
ジェニファー アール． ジャン，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59714166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6716785(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ギリアード サイエンシーズ， インコーポレイテッド, ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2019528280A publication Critical patent/JP2019528280A/ja
Publication of JP2019528280A5 publication Critical patent/JP2019528280A5/ja
Application granted granted Critical
Publication of JP6716785B2 publication Critical patent/JP6716785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019508953A 2016-08-19 2017-08-17 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 Active JP6716785B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662377312P 2016-08-19 2016-08-19
US62/377,312 2016-08-19
US201762457555P 2017-02-10 2017-02-10
US62/457,555 2017-02-10
PCT/US2017/047416 WO2018035359A1 (en) 2016-08-19 2017-08-17 Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020048130A Division JP2020111592A (ja) 2016-08-19 2020-03-18 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物

Publications (3)

Publication Number Publication Date
JP2019528280A JP2019528280A (ja) 2019-10-10
JP2019528280A5 JP2019528280A5 (enExample) 2019-12-12
JP6716785B2 true JP6716785B2 (ja) 2020-07-01

Family

ID=59714166

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019508953A Active JP6716785B2 (ja) 2016-08-19 2017-08-17 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP2020048130A Withdrawn JP2020111592A (ja) 2016-08-19 2020-03-18 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP2020175151A Pending JP2021008516A (ja) 2016-08-19 2020-10-19 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP2022172416A Withdrawn JP2023011754A (ja) 2016-08-19 2022-10-27 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP2024148326A Pending JP2024170471A (ja) 2016-08-19 2024-08-30 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020048130A Withdrawn JP2020111592A (ja) 2016-08-19 2020-03-18 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP2020175151A Pending JP2021008516A (ja) 2016-08-19 2020-10-19 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP2022172416A Withdrawn JP2023011754A (ja) 2016-08-19 2022-10-27 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP2024148326A Pending JP2024170471A (ja) 2016-08-19 2024-08-30 Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物

Country Status (43)

Country Link
US (4) US10071985B2 (enExample)
EP (3) EP4265299A3 (enExample)
JP (5) JP6716785B2 (enExample)
KR (5) KR20200131351A (enExample)
CN (3) CN109890808B (enExample)
AU (5) AU2017312102B2 (enExample)
BR (2) BR112018071678B1 (enExample)
CA (1) CA3021227C (enExample)
CL (1) CL2019000415A1 (enExample)
CO (1) CO2019001379A2 (enExample)
CR (1) CR20190084A (enExample)
CY (2) CY1122296T1 (enExample)
DK (2) DK3347352T3 (enExample)
DO (1) DOP2019000033A (enExample)
EC (1) ECSP19011209A (enExample)
ES (2) ES2954514T3 (enExample)
FI (1) FI3597646T3 (enExample)
FR (1) FR22C1063I2 (enExample)
HK (1) HK1256904B (enExample)
HR (1) HRP20231018T1 (enExample)
HU (3) HUE045137T2 (enExample)
IL (1) IL264644B (enExample)
JO (1) JOP20180123A1 (enExample)
LT (3) LT3597646T (enExample)
LU (1) LUC00292I2 (enExample)
MA (2) MA42795B1 (enExample)
MX (1) MX369307B (enExample)
MY (1) MY191466A (enExample)
NL (1) NL301212I2 (enExample)
NO (1) NO2022059I1 (enExample)
NZ (1) NZ750706A (enExample)
PE (2) PE20211427A1 (enExample)
PH (2) PH12021552802A1 (enExample)
PL (2) PL3597646T3 (enExample)
PT (2) PT3347352T (enExample)
SA (1) SA519401123B1 (enExample)
SG (2) SG11201808944QA (enExample)
SI (2) SI3347352T1 (enExample)
TW (5) TWI715944B (enExample)
UA (1) UA121630C2 (enExample)
UY (1) UY37367A (enExample)
WO (1) WO2018035359A1 (enExample)
ZA (1) ZA201901430B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
PL3597646T3 (pl) 2016-08-19 2023-12-11 Gilead Sciences, Inc. Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
WO2019246545A1 (en) * 2018-06-21 2019-12-26 Drexel University Small-molecule hiv-1 capsid protein inhibitors and methods using same
CN120053446A (zh) * 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
CA3108633A1 (en) * 2018-08-09 2020-02-13 Viiv Healthcare Uk (No 5) Limited Inhibitors of human immunodeficiency virus replication
EP3849982A1 (en) 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
MX2021004679A (es) * 2018-10-22 2021-07-15 Univ Nebraska Profarmacos antivirales y nanoformulaciones de las mismas.
JP7532354B2 (ja) * 2018-10-24 2024-08-13 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210393633A1 (en) 2018-10-25 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210403465A1 (en) 2018-10-29 2021-12-30 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
WO2020095177A1 (en) 2018-11-05 2020-05-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210379071A1 (en) 2018-11-05 2021-12-09 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
CR20210486A (es) 2019-03-22 2021-12-07 Gilead Sciences Inc Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico
US20220211704A1 (en) 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
PE20220510A1 (es) 2019-06-19 2022-04-07 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana
ES2974657T3 (es) 2019-10-01 2024-07-01 Viiv Healthcare Uk No 5 Ltd Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
EP4038068A1 (en) 2019-10-01 2022-08-10 VIIV Healthcare UK (No.5) Limited N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
TW202128648A (zh) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
JP2022551691A (ja) 2019-10-08 2022-12-13 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
KR20220106165A (ko) * 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
CA3162126A1 (en) 2019-11-29 2021-06-03 Jiangsu Hengrui Medicine Co., Ltd. Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof
CN116098917A (zh) * 2020-02-27 2023-05-12 河南真实生物科技有限公司 核苷类化合物在治疗冠状病毒感染性疾病中的用途
WO2021176367A1 (en) 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2021231447A1 (en) 2020-03-06 2022-09-22 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
MX2022012881A (es) 2020-04-15 2022-11-08 Viiv Healthcare Uk No 5 Ltd Inhibidores de replicacion del virus de inmunodeficiencia humana.
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CA3181690A1 (en) * 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4244396B1 (en) 2020-11-11 2025-08-13 Gilead Sciences, Inc. Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
EP4281083A4 (en) 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS
EP4361140A4 (en) * 2021-05-28 2025-09-03 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF FUSED CYCLIC PYRIDINE DERIVATIVE AND PROCESS FOR PREPARATION THEREOF
KR20230019059A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물
KR20230018690A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물
CA3234219A1 (en) * 2021-10-13 2023-04-20 Gautam Dalwadi Inhibitors of human immunodeficiency virus replication
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
JP2025527677A (ja) 2022-08-26 2025-08-22 ギリアード サイエンシーズ， インコーポレイテッド 広域中和抗体のための投与及びスケジューリングレジメン
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
KR20240061218A (ko) 2022-10-31 2024-05-08 주식회사 이보드 복합 단열재 및 제조방법
WO2024163262A2 (en) 2023-01-30 2024-08-08 Merck Sharp & Dohme Llc Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors
US20240390349A1 (en) 2023-04-19 2024-11-28 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
US20250011353A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Process of preparing hiv capsid inhibitor
CN121219281A (zh) 2023-05-31 2025-12-26 吉利德科学公司 用于治疗hiv的化合物的固体形式
CN116675675A (zh) * 2023-06-05 2023-09-01 北京康立生医药技术开发有限公司 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法
WO2024257009A1 (en) 2023-06-15 2024-12-19 VIIV Healthcare UK (No.5) Limited Methods and intermediates for preparing compounds
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025038715A1 (en) 2023-08-15 2025-02-20 Gilead Sciences, Inc. Pharmaceutical formulations of bictegravir and lenacapavir
EP4529922A1 (en) 2023-09-29 2025-04-02 Gilead Sciences, Inc. Pharmaceutical formulations of bictegravir and lenacapavir
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
KR20250040288A (ko) 2023-09-15 2025-03-24 민영호 복합 단열재
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250367385A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240389A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367384A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240393A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367386A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE69115694T2 (de) 1990-06-13 1996-10-17 Arnold Newton Mass. Glazier Phosphorylierte prodrugs
DE10399025I2 (de) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
NZ536942A (en) 2000-07-21 2006-03-31 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
EP1399420B1 (en) 2001-06-27 2007-12-05 SmithKline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
US7183290B2 (en) 2001-06-27 2007-02-27 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
CN1972956A (zh) 2004-02-27 2007-05-30 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的新化合物
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
BRPI0512690A (pt) 2004-07-27 2007-11-27 Gilead Sciences Inc análogos de fosfonato de compostos inibidores de hiv
US8067587B2 (en) 2005-07-28 2011-11-29 Lenroc Company Process for the production of monoalkali metal cyanurates
WO2007018998A2 (en) 2005-08-05 2007-02-15 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
KR20080087817A (ko) 2005-12-14 2008-10-01 브리스톨-마이어스 스큅 컴퍼니 인자 ｘｉａ 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체
CA2648569C (en) 2006-04-12 2012-02-07 Merck & Co., Inc. Pyridyl amide t-type calcium channel antagonists
US7647464B2 (en) 2006-04-28 2010-01-12 At&T Intellectual Property, I,L.P. Methods, systems, and products for recording media to a restoration server
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CN101702908A (zh) 2007-03-23 2010-05-05 麻萨诸塞州大学 Hiv-1蛋白酶抑制剂
BRPI0813733A2 (pt) 2007-06-29 2019-11-05 Gilead Sciences Inc composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso.
EP2175857B1 (en) 2007-07-12 2013-09-11 Janssen R&D Ireland Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
RU2010120671A (ru) 2007-10-24 2011-11-27 Мерк Шарп Энд Домэ Корп. (Us) Гетероциклические фениламидные антагонисты кальциевых каналов т-типа
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
CN102026996B (zh) 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
US20120045761A1 (en) 2009-02-25 2012-02-23 Bigtec Private Limited Probes and primers for detection of chikungunya
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
NZ604716A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
HUE032948T2 (en) 2011-03-23 2017-11-28 Trevena Inc Opioid receptor ligands and methods of using and making same
AP2013007249A0 (en) 2011-04-21 2013-11-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
KR101612642B1 (ko) 2011-08-16 2016-04-14 길리애드 사이언시즈, 인코포레이티드 테노포비어 알라펜아미드 헤미푸마레이트
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
SG11201401189WA (en) 2012-04-20 2014-09-26 Gilead Sciences Inc Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
WO2014028931A2 (en) 2012-08-17 2014-02-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
AR094311A1 (es) 2012-12-27 2015-07-22 Japan Tobacco Inc Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv
NZ631762A (en) 2013-01-09 2017-02-24 Gilead Sciences Inc 5-membered heteroaryls and their use as antiviral agents
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
KR20160078382A (ko) 2013-10-24 2016-07-04 브리스톨-마이어스 스큅 컴퍼니 인간 면역결핍 바이러스 복제의 억제제
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN107207498B (zh) 2014-12-24 2020-03-24 吉利德科学公司 用于治疗hiv的稠合嘧啶化合物
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
EP3286166B1 (en) 2015-04-23 2020-05-13 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
KR20180005195A (ko) 2015-04-23 2018-01-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
EP3456717B1 (en) * 2015-07-06 2021-03-17 Gilead Sciences, Inc. 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
US10171985B1 (en) 2015-07-22 2019-01-01 Ginko LLC Method and apparatus for data sharing
PL3597646T3 (pl) 2016-08-19 2023-12-11 Gilead Sciences, Inc. Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
US10911396B2 (en) 2018-06-28 2021-02-02 Paypal, Inc. Mid-tier messaging system
CN120053446A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv

Also Published As

Publication number Publication date
AU2023271739B2 (en) 2025-08-21
JOP20180123A1 (ar) 2019-01-30
HK1256904B (en) 2020-07-17
CN109890808B (zh) 2020-08-07
LTPA2023501I1 (enExample) 2023-02-10
EP3347352B1 (en) 2019-07-03
MX2018012905A (es) 2019-01-30
US10071985B2 (en) 2018-09-11
SG10201912535VA (en) 2020-02-27
NZ763251A (en) 2025-02-28
NZ750706A (en) 2020-07-31
MA50673A (fr) 2020-08-05
JP2021008516A (ja) 2021-01-28
HUS2200053I1 (hu) 2023-01-28
ECSP19011209A (es) 2019-02-28
MA42795B1 (fr) 2019-08-30
AU2020202331A1 (en) 2020-04-23
ES2746374T3 (es) 2020-03-05
KR20250085838A (ko) 2025-06-12
FR22C1063I2 (fr) 2023-12-15
EP4265299A3 (en) 2024-01-17
BR122020001791B1 (pt) 2022-01-25
TWI664966B (zh) 2019-07-11
NL301212I1 (enExample) 2023-01-12
AU2017312102A1 (en) 2019-03-07
NL301212I2 (nl) 2023-04-06
CR20190084A (es) 2019-05-02
MY191466A (en) 2022-06-28
FI3597646T3 (fi) 2023-09-07
EP3597646B1 (en) 2023-06-21
DK3347352T3 (da) 2019-08-26
TW202342449A (zh) 2023-11-01
SI3597646T1 (sl) 2023-10-30
NZ791314A (en) 2025-03-28
SG11201808944QA (en) 2018-11-29
AU2020202331C1 (en) 2021-08-26
LTC3347352I2 (enExample) 2024-10-10
KR102180740B1 (ko) 2020-11-20
US10654827B2 (en) 2020-05-19
JP2020111592A (ja) 2020-07-27
KR20240070646A (ko) 2024-05-21
LUC00292I2 (enExample) 2025-05-12
CN109890808A (zh) 2019-06-14
WO2018035359A1 (en) 2018-02-22
TW201811327A (zh) 2018-04-01
PH12021552802A1 (en) 2022-07-04
PT3347352T (pt) 2019-09-24
CA3021227C (en) 2020-11-03
UY37367A (es) 2018-03-23
FR22C1063I1 (fr) 2023-02-03
HUE063811T2 (hu) 2024-02-28
MX369307B (es) 2019-11-05
JP2023011754A (ja) 2023-01-24
CY1122296T1 (el) 2021-01-27
TWI715944B (zh) 2021-01-11
ZA201901430B (en) 2021-09-29
CN111793061B (zh) 2024-11-26
TWI853404B (zh) 2024-08-21
PL3347352T3 (pl) 2019-12-31
US20240376077A1 (en) 2024-11-14
EP3347352A1 (en) 2018-07-18
BR112018071678B1 (pt) 2021-01-26
US11993583B2 (en) 2024-05-28
CN111793061A (zh) 2020-10-20
US20180051005A1 (en) 2018-02-22
AU2020202331B2 (en) 2021-05-27
KR20230011471A (ko) 2023-01-20
AU2017312102B2 (en) 2020-03-05
PE20211427A1 (es) 2021-08-03
HRP20231018T1 (hr) 2023-12-08
PL3597646T3 (pl) 2023-12-11
AU2021221855B2 (en) 2023-08-31
CN119462611A (zh) 2025-02-18
AU2021221855A1 (en) 2021-09-23
BR112018071678A2 (pt) 2019-02-19
JP2019528280A (ja) 2019-10-10
CO2019001379A2 (es) 2019-02-19
PH12019500335A1 (en) 2019-11-11
HUE045137T2 (hu) 2019-12-30
UA121630C2 (enExample) 2020-06-25
CY2022039I2 (el) 2023-01-27
CY2022039I1 (el) 2023-01-27
US20180370950A1 (en) 2018-12-27
EP4265299A2 (en) 2023-10-25
NZ791323A (en) 2025-03-28
NO2022059I1 (no) 2022-12-16
KR20200131351A (ko) 2020-11-23
EP3597646A1 (en) 2020-01-22
SA519401123B1 (ar) 2022-11-09
TW202138365A (zh) 2021-10-16
LT3597646T (lt) 2023-09-25
IL264644B (en) 2019-09-26
US20200262815A1 (en) 2020-08-20
ES2954514T3 (es) 2023-11-22
DOP2019000033A (es) 2019-03-15
AU2023271739A1 (en) 2023-12-14
TW201922711A (zh) 2019-06-16
AU2025271141A1 (en) 2025-12-18
LT3347352T (lt) 2019-08-12
SI3347352T1 (sl) 2019-08-30
DK3597646T3 (da) 2023-09-04
KR20190039431A (ko) 2019-04-11
CA3021227A1 (en) 2018-02-22
TW202504608A (zh) 2025-02-01
JP2024170471A (ja) 2024-12-10
MA42795A (fr) 2019-07-03
PT3597646T (pt) 2023-09-11
PE20190910A1 (es) 2019-06-26
CL2019000415A1 (es) 2019-06-21

Similar Documents

Publication Publication Date Title
JP6716785B2 (ja) Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP6933770B2 (ja) Ｈｉｖカプシド阻害剤のコリン塩形態
JP2021530523A (ja) Ｈｉｖの処置のためのカプシド阻害剤
HK1256904A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
HK40099977A (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
HK40018878A (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EA036921B1 (ru) Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191030

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200123

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200610

R150 Certificate of patent or registration of utility model

Ref document number: 6716785

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250